Arikayce
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM. These infections can present in a variety of patients, including those with cystic fibrosis, although Insmed is excluding these patients from its trials. Insmed has also conducted trials of Arikayce for the specific treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients. However, this indication has been deprioritized in favor of further developing the drug for the NTM market opportunity.
CONTENTS
4 OVERVIEW
4 Drug Overview
5 Product Profiles
5 Arikayce : Cystic fibrosis
LIST OF FIGURES
8 Figure 1: Arikayce for cystic fibrosis – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary of Arikayce for cystic fibrosis
10 Figure 3: Datamonitor Healthcare’s drug assessment summary of Arikayce for cystic fibrosis
LIST OF TABLES
6 Table 1: Arikayce drug profile
7 Table 2: Arikayce Phase III data in cystic fibrosis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Vertex triple combinations 
Sign up to the